ONCOCYTE CORP's ticker is OCX and the CUSIP is 68235C107. A total of 2 filers reported holding ONCOCYTE CORP in Q3 2023. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $10,281 | -31.6% | 44,700 | +5.4% | 0.00% | – |
| Q1 2023 | $15,027 | +7.3% | 42,400 | -1.2% | 0.00% | – |
| Q4 2022 | $14,000 | -58.8% | 42,900 | -6.5% | 0.00% | – |
| Q3 2022 | $34,000 | +183.3% | 45,900 | +232.6% | 0.00% | – |
| Q2 2022 | $12,000 | -42.9% | 13,800 | -0.9% | 0.00% | – |
| Q1 2022 | $21,000 | -30.0% | 13,930 | +1.9% | 0.00% | – |
| Q4 2021 | $30,000 | -38.8% | 13,670 | -0.7% | 0.00% | – |
| Q3 2021 | $49,000 | -70.1% | 13,770 | -79.9% | 0.00% | – |
| Q4 2020 | $164,000 | +70.8% | 68,470 | -0.7% | 0.00% | – |
| Q3 2020 | $96,000 | -26.7% | 68,975 | +0.6% | 0.00% | – |
| Q2 2020 | $131,000 | -23.8% | 68,580 | -2.1% | 0.00% | – |
| Q1 2020 | $172,000 | +11.7% | 70,080 | +2.3% | 0.00% | – |
| Q4 2019 | $154,000 | +6.2% | 68,510 | -0.4% | 0.00% | – |
| Q3 2019 | $145,000 | -13.7% | 68,810 | +2.2% | 0.00% | – |
| Q2 2019 | $168,000 | -36.8% | 67,300 | 0.0% | 0.00% | – |
| Q1 2019 | $266,000 | – | 67,300 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| BROADWOOD CAPITAL INC | 14,716,204 | $20,456,000 | 1.61% |
| PURA VIDA INVESTMENTS, LLC | 6,022,534 | $8,371,000 | 0.43% |
| P.A.W. CAPITAL CORP | 199,700 | $278,000 | 0.30% |
| Penbrook Management LLC | 229,425 | $319,000 | 0.28% |
| PERKINS CAPITAL MANAGEMENT INC | 39,725 | $55,000 | 0.05% |
| GSA CAPITAL PARTNERS LLP | 201,047 | $279,000 | 0.05% |
| Private Wealth Partners, LLC | 150,000 | $209,000 | 0.02% |
| Phoenix Holdings Ltd. | 317,138 | $426,000 | 0.02% |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | 255,300 | $355,000 | 0.01% |
| ETF MANAGERS GROUP, LLC | 157,933 | $226,000 | 0.01% |